Victoria N Karetnikova

List of Publications by Year
in descending order

30	166	1162367	1125271
papers	citations	8	13
		h-index	g-index

34	34	34	320
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases, 2020, 9, 17-28.	0.3	24
2	Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids in Health and Disease, 2014, 13, 111.	1.2	23
3	Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. Annals of Laboratory Medicine, 2016, 36, 313-319.	1.2	17
4	Glucose levels as a prognostic marker in patients with ST-segment elevation myocardial infarction: a case–control study. BMC Endocrine Disorders, 2016, 16, 31.	0.9	17
5	The role of adipose tissue and adipokines in the manifestation of type 2 diabetes in the long-term period following myocardial infarction. Diabetology and Metabolic Syndrome, 2016, 8, 24.	1.2	17
6	Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction. Frontiers in Pharmacology, 2016, 7, 324.	1.6	16
7	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	0.4	12
8	Dose-dependent effects of atorvastatin on myocardial infarction. Drug Design, Development and Therapy, 2015, 9, 3361.	2.0	8
9	Relationship key factor of inflammation and the development of complications in the late period of myocardial infarction in patients with visceral obesity. BMC Cardiovascular Disorders, 2017, 17, 36.	0.7	8
10	Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction. Disease Markers, 2016, 2016, 1-6.	0.6	4
11	Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. Russian Journal of Cardiology, 2020, 25, 31-40.	0.4	4
12	Association of inflammatory markers and poor outcome in diabetic patients presenting with ST segment elevation myocardial infarction. Journal of Inflammation Research, 2015, 8, 107.	1.6	3
13	Fibrosis biomarkers and global myocardial strain in the diagnosis and prediction of diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction. Russian Journal of Cardiology, 2021, 26, 4255.	0.4	2
14	Biological markers and cardiac remodelling following the myocardial infarction. Aging, 2019, 11, 3523-3535.	1.4	2
15	Visceral adiposity index in patients with coronary artery disease, obesity and type 2 diabetes. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2311.	0.4	2
16	N-terminal propeptide of type III procollagen for predicting diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2494.	0.4	1
17	The Congress of the American College of Cardiology in review. Complex Issues of Cardiovascular Diseases, 2020, 9, 29-37.	0.3	1
18	The importance of chronic kidney disease for the assessment of risk of adverse outcomes after myocardial infarction. Klinicheskaia Meditsina, 2017, 95, 563-570.	0.2	1

#	Article	IF	Citations
19	The relationship of the epicardial fat and adipo-fibrokines in myocardial infarction. Klinichescheskaya Laboratornaya Diagnostika, 2020, 65, 533-540.	0.2	1
20	Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction. Russian Journal of Cardiology, 2021, 26, 4137.	0.4	0
21	Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction. Fundamental and Clinical Medicine, 2021, 6, 46-55.	0.1	0
22	CORRELATION OF INFLAMMATION MARKERS AND THE LEVEL OF DIFFUSIONAL CAPACITY OF LUNGS IN PATIENTS WITH MYOCARDIAL INFARCTION. Siberian Medical Review, 2018, , 11-16.	0.1	0
23	POST-INFARCTION REMODELLING AND DIFFUSION CAPACITY OF THE LUNGS: IS THERE ANY CONNECTION?. Siberian Medical Review, 2018, , 66-72.	0.1	0
24	RELATION OF THE MARKERS OF MYOCARDIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION WITH STRUCTURAL AND FUNCTIONAL PARAMETERS OF THE LUNGS IN MYOCARDIAL INFARCTION PATIENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 24-28.	0.4	0
25	The factors inflyencing the diffusion capacity of the lung in patients with myocardial infarction.. Klinicheskaia Meditsina, 2018, 96, 328-334.	0.2	0
26	Outcomes of long-term observation period in patients with myocardial infarction undergone radiopaque interventions in the acute period of the disease.. Klinicheskaia Meditsina, 2018, 96, 648-657.	0.2	0
27	Prevalence of electrocardiographic changes in Kemerovo region according to the data of the ESSE-RF study. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 120-126.	0.4	0
28	Serum procollagens, structural and functional characteristics of the heart in prediction of cardiac fibrosis after myocardial infarction. Siberian Medical Review, 2020, , 75-82.	0.1	0
29	In-hospital changes of echocardiographic parameters and their relationship with the procollagen I C-terminal propeptide in patients with myocardial infarction and preserved left ventricle systolic function. Russian Journal of Cardiology, 2020, 25, 45-51.	0.4	0
30	Educational approaches to teaching specialist program â€œÐ¡ardiology and cardiovascular surgeryâ€• during lockdown. Complex Issues of Cardiovascular Diseases, 2020, 9, 90-95.	0.3	0